Table 2.
Genotype and allele frequencies of CETP in CAD patient and BD groups
| Genotype/allele | CAD | BD | Inheritance model | OR (95% CI) | P | |
|---|---|---|---|---|---|---|
| CETP rs1532624 | ||||||
| CC | 77 (32.49%) | 52 (23.21%) | Dominant versus AC + AA | 1.59 (1.05–2.40) | 0.026* | |
| CA | 119 (50.21%) | 128 (57.14%) | Additive, versus CC | 0.63 (0.41–0.97) | 0.033* | |
| AA | 41 (17.30%) | 44 (19.64%) | Additive, versus CC | 0.63 (0.36–1.10) | 0.10 | |
| CC + CA | 196 (82.70%) | 180 (81.08%) | Recessive,versus AA | 1.17 (0.73–1.87) | 0.52 | |
| C | 273 (57.59%) | 232(51.79%) | – | 1.27 (0.97–1.64) | 0.076 | |
| A | 201 (42.41%) | 216 (48.21%) | – | 0.79 (0.61–1.03) | 0.076 | |
| CETP rs247616 | ||||||
| CC | 119 (50.64%) | 75 (35.21%) | Dominant, versus CT + TT | 1.89 (1.29–2.76) | 0.001* | |
| CT | 94 (40.00%) | 112 (52.58%) | Additive, versus CC | 0.53 (0.36–0.79) | 0.002* | |
| TT | 22 (9.36%) | 26 (12.21%) | Additive, versus CC | 0.53 (0.28–1.01) | 0.05 | |
| CC + CT | 213 (90.64%) | 187 (87.79%) | Recessive, versus TT | 1.35 (0.74–2.46) | 0.33 | |
| C | 332 (70.64%) | 262 (61.50%) | – | 1.51 (1.14–1.99) | 0.003* | |
| T | 138 (29.32%) | 164 (38.50%) | – | 0.66 (0.50–0.88) | 0.003* | |
| CETP rs708272 | ||||||
| CC | 80 (33.47%) | 63 (26.25%) | Dominant; versus TC + TT | 1.41 (0.95–2.09) | 0.084 | |
| CT | 123 (51.46%) | 131 (45.58%) | Additive versus CC | 0.74 (0.49–1.12) | 0.15 | |
| TT | 36 (15.06%) | 46 (19.17%) | Additive versus CC | 0.61 (0.26–1.07) | 0.08 | |
| CC + CT | 203 (84.94%) | 194(80.83%) | Recessive versus TT | 1.49 (0.92–2.41) | 0.10 | |
| C | 283 (59.21%) | 257 (53.54%) | – | 1.26 (0.97–1.63) | 0.077 | |
| T | 195 (40.79%) | 223 (46.46%) | – | 0.79 (0.61–1.03) | 0.077 | |
CAD coronary artery disease patient group, BD blood donor group
*Differences statistically significant (p < 0.05)